AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 251 min read$ALLO

Douglas Earl Martin sold $63K of ALLO

Douglas Earl Martin (SVP, General Counsel) sold 29,697 shares of Allogene Therapeutics, Inc. (ALLO) at $2.12 on 2026-08-21.

Original reporting
SEC EDGAR · Douglas Earl Martin
Published Aug 25, 2026, 8:43 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 8:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ALLO
Neutral
high confidence
Mentioned
$ALLO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALLONeutralLow
01

Why it matters

The sale represents a routine liquidity event; no new strategic information disclosed.

02

Market read

Low relevance; minor insider transaction with limited market impact.

03

What to watch

Potential upcoming clinical data releases may dominate price movement.

Relevance 3/10Novelty 4/10Timing: filed today

Background

Form 4 filings disclose insider transactions; traders monitor for material changes.

Company-level read

Ticker impact

$ALLONeutralHigh confidence
Context

SVP General Counsel Douglas Earl Martin sold 29,697 shares of Allogene Therapeutics for $62,957 on 2026-08-21.

Expected impact

No significant impact expected.

Evidence & confidence

Sale size is small relative to total holdings and market cap; insider remains a large holder.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; US market unaffected.

Global

None

Counterpoint

What could challenge this read

Insider sale could signal internal concerns, but size is too small to act on.

Key entities

  • Company
    Allogene Therapeutics, Inc.

    Biotech firm developing allogeneic CAR T therapies.

  • Insider
    Douglas Earl Martin

    Senior Vice President, General Counsel at Allogene.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALLO insider trading history →

Related articles

AUG 19
$ALLOMedAI 8/10

Allogene (ALLO) Q2 2026 Earnings Call Transcript

Allogene (ALLO) reported a Q2 2026 net loss of $42.7M, or $0.13 per share, with $4.6M in collaboration revenue. Cash reserves totaled $423.6M, providing a runway into 2029. Key clinical updates include 58.3% MRD negativity in the ALPHA3 trial and a 31% ORR for ALLO-316. The company aims to expand access to CAR T therapies in community settings. FDA granted RMAT and Fast Track designations for cema-cel. Management highlighted upcoming milestones and risks, including small data sets and safety cha

fool.com2 min
AUG 13
$ALLOMed

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

Allogene Therapeutics (ALLO) reported Q2 2026 EPS loss of 13 cents, narrower than the Zacks Consensus loss of 16 cents, helped by lower R&D costs. Collaboration revenue from related parties was $4.6 million. Cash, cash equivalents and investments rose to $423.6 million after a $200.4 million April offering. The company reiterated 2026 operating expense guidance and expects ALPHA3 interim EFS data in mid-2027.

tradingview.com6 min
AUG 12
$ALLOMed

Allogene Therapeutics, Inc. (ALLO): Results of Operations and Financial Condition

Allogene Therapeutics, Inc. (ALLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update • Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): ◦ Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatien

SEC EDGAR 8-K6 min